Table S1. Efficacy of first-line chemotherapy in RM/NPC in Asia versus non-Asia regions.

Regimen	ORR				DCR				6-month PFS rate				1-year OS rate
	Asia	Non-Asia	P		Asia	Non-Asia	P		Asia	Non-Asia	P		Asia	Non-Asia	P
FP	0.44	–	–		0.88	–	–		0.53	–	–		0.63	–	–
GP	0.57	0.37	0.098		0.84	0.95	0.328		0.71	0.47	0.040		0.69	0.79	0.448
TP	0.67	0.22	0.011		0.92	–	–		0.50	–	–		0.79	0.78	1.000
Triplet combination regimen	0.80	0.52	<0.001		0.92	0.86	0.239		0.86	0.73	0.067		0.81	0.52	<0.001

^†, these pooled data derived from studies using WHO criteria as efficacy evaluation tool. R/M NPC, recurrent or metastatic nasopharyngeal carcinoma; FP, 5-fluorouracil plus platinum; GP, Gemcitabine plus platinum; TP, taxanes plus platinum; ORR, objective response rate; DCR, disease control rate; PFS, progression free survival; OS, overall survival.